Company Description
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally.
The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.
It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic.
The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution.
It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies.
The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt.
As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
| Country | Israel |
| Founded | 1959 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,554 |
| CEO | Uday V. Baldota |
Contact Details
Address: 14 Haktor St Haifa Bay, L3 26110 Israel | |
| Phone | 9143459001 |
| Website | taro.com |
Stock Details
| Ticker Symbol | TARO |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0000906338 |
| CUSIP Number | M8737E108 |
| ISIN Number | IL0010827181 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Uday V. Baldota | Chief Executive Officer and Director |
| William J. Coote | Vice President, Chief Financial Officer and Chief Accounting Officer |
| Itamar Karsenti | Vice President and Head of Operations |
| Avi Avramoff | Vice President and Head of Research & Development |
| Itzik Baruch | Vice President of Technical Services |
| Dr. Roman Kaplan | Vice President of Scientific and Technical Compliance Manager |
| Erik Zwicker J.D. | Vice President, General Counsel and Secretary |
| Ara Aprahamian | Vice President of Sales and Marketing |
| Michele Visosky | Vice President and Head of Human Resource |
| Jayesh Shah | Head of Procurement |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |
| Mar 20, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |
| Mar 11, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |
| Feb 15, 2024 | SC 13E3 | Going private transaction by certain issuers |
| Jan 26, 2024 | 6-K | Report of foreign issuer |
| Jan 17, 2024 | 6-K | Report of foreign issuer |
| Jan 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 4, 2024 | 6-K | Report of foreign issuer |
| Dec 11, 2023 | 6-K | Report of foreign issuer |
| Dec 11, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |